Melanotan II Melanocortin Research: Published Studies Reviewed
A factual review of peer-reviewed studies investigating Melanotan II, a synthetic α-MSH analog, in melanocortin receptor pharmacology, skin pigmentation models, and photoprotection research.
Melanotan II: Overview
Melanotan II (MT-II) is a cyclic heptapeptide and synthetic analog of alpha-melanocyte stimulating hormone (α-MSH), an endogenous neuropeptide derived from pro-opiomelanocortin (POMC) cleavage. MT-II was developed in the 1980s at the University of Arizona as part of a program to investigate potent, stable melanocortin receptor ligands. It binds with high affinity to melanocortin receptor subtypes MC1R, MC3R, MC4R, and MC5R — a non-selective profile that has made it a pharmacological tool in multiple research contexts.
The following review presents key findings from published research without therapeutic claims or dosage recommendations.
Study 1: MC1R Agonism and Melanogenesis in Keratinocyte Models
Sawyer et al. (1982) first characterized Melanotan II's potency at melanocortin receptors. Subsequent cell culture studies examined its effects on MC1R-expressing melanocytes — the primary cells responsible for melanin synthesis and skin pigmentation.
Key observations included:
- Dose-dependent increase in melanin synthesis in MC1R+ cell cultures
- Activation of cAMP/PKA signaling cascade downstream of MC1R
- Increased tyrosinase, TRP-1, and TRP-2 gene expression
- Enhanced melanosome maturation and transfer to keratinocytes in co-culture models
- Significantly greater potency than endogenous α-MSH at MC1R
Study 2: UV Photoprotection Mechanisms in Melanocyte Studies
Dvorak et al. (1999) and related studies investigated whether MC1R activation-induced melanogenesis could provide measurable photoprotection in experimental models.
Research findings included:
- Eumelanin:pheomelanin ratio shift toward eumelanin following MC1R activation
- Eumelanin's superior UV absorption properties well-characterized in photophysical studies
- Enhanced melanosome distribution to upper epidermal layers in activated vs. control cultures
- MC1R variants (particularly R151C, R160W, D294H) associated with reduced α-MSH responsiveness in human genetics data
Additional note: MC1R genetic variants that reduce responsiveness to α-MSH are among the strongest genetic risk factors for melanoma, establishing the importance of this pathway in photoprotection research.
Melanocortin Receptor Subtype Pharmacology
MT-II's non-selective binding profile across multiple melanocortin receptor subtypes has made it a research tool for studying MC receptor pharmacology in various tissue contexts.
| Receptor | Primary Distribution | Research Context |
|---|---|---|
| MC1R | Melanocytes, skin | Pigmentation, photoprotection; primary focus of Melanotan II skin research |
| MC3R | Hypothalamus, gut | Energy homeostasis and feeding behavior research |
| MC4R | Brain (widespread) | Appetite regulation, energy expenditure; extensively studied independently |
| MC5R | Exocrine glands | Sebaceous gland, sweat gland function research |
Note: MT-II's activity at MC4R has made it a tool compound in neuropharmacology research on energy balance and feeding behavior, independent of its pigmentation effects. This is a distinct research context from its MC1R-mediated skin pigmentation pharmacology.
Molecular Profile
| Property | Value |
|---|---|
| Type | Cyclic heptapeptide (cyclized via lactam bridge) |
| Molecular weight | 1,024.2 Da |
| Primary receptor targets | MC1R, MC3R, MC4R, MC5R (non-selective) |
| Relative to endogenous α-MSH | Greater receptor potency and longer plasma half-life |
| Storage | Lyophilized: -20°C; Reconstituted: 2–8°C, use within 30 days |
Quick Reference Summary
- Mechanism: Potent non-selective melanocortin receptor agonist (MC1–5R)
- Primary skin research: MC1R agonism increases eumelanin synthesis via cAMP/MITF/tyrosinase pathway
- Photoprotection research: Eumelanin UV absorption properties studied in cell models
- Receptor profile: Multi-receptor binding used as tool compound in multiple research contexts
- Potency: Substantially greater than endogenous α-MSH at MC1R
- Use context: Research-grade compound for in vitro and preclinical laboratory use only